A diversified medical device company; develops, manufactures and markets products for the surgical and interventional treatment of disease. Business is conducted in two reportable segments, the surgical business and the interventional business.
The best Bull and Bear pitches based on recency and number of recommendations.
Speculating on growth from new acquisition.$59M cash - no debt. Cash per share = $5. Renewed focus on direct sales that has proven a past successful growth model. Pegasus acquisition will still hit expenses hard for Q4 09 & Q1 10, but future… More
Financial secure company with nearly $4 per share in cash, but technically likely to retrace 8-12% from current $16.30 levels; fudamentally not a "cheap one" even with 39% 3rd quarter revenue growth.
Read the most recent pitches from players about SYNO.DL.
Find the members with the highest scoring picks in SYNO.DL.
See what the Wall Street professionals think, according to their public statements and filings.